CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2020	Jun. 30, 2019	Jun. 28, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues	[1]	$ 11,801	$ 13,264	$ 23,829	$ 26,382
Costs and expenses:
Cost of sales	[1],[2]	2,281	2,576	4,658	5,009
Selling, informational and administrative expenses	[1],[2]	3,030	3,511	5,903	6,850
Research and development expenses	[1],[2]	2,132	1,842	3,856	3,544
Amortization of intangible assets	[1]	905	1,184	1,790	2,367
Restructuring charges and certain acquisition-related costs	[1]	362	(115)	431	(69)
(Gain) on completion of Consumer Healthcare JV transaction	[1]	0	0	(6)	0
Other (income)/deductions––net	[1]	(862)	126	(641)	218
Income from continuing operations before provision/(benefit) for taxes on income	[1],[3]	3,953	4,141	7,838	8,463
Provision/(benefit) for taxes on income	[1]	519	(915)	993	(481)
Income from continuing operations	[1]	3,434	5,056	6,845	8,945
Discontinued operations––net of tax	[1]	0	0	0	0
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	3,434	5,056	6,845	8,945
Less: Net income attributable to noncontrolling interests	[1]	8	10	17	15
Net income attributable to Pfizer Inc.	[1]	$ 3,426	$ 5,046	$ 6,828	$ 8,929
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.62	$ 0.91	$ 1.23	$ 1.59
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.62	0.91	1.23	1.59
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.61	0.89	1.22	1.56
Discontinued operations––net of tax (in dollars per share)	[1]	0	0	0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.61	$ 0.89	$ 1.22	$ 1.56
Weighted-average shares––basic	[1]	5,554	5,562	5,550	5,598
Weighted-average shares––diluted	[1]	5,619	5,672	5,616	5,711

[1] Amounts may not add due to rounding.

[2] Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

[3] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income of $76 million in the second quarter of 2020 and $76 million in the second quarter of 2019, and $153 million in the first six months of 2020 and $140 million in the first six months of 2019 from our investment in ViiV. For additional information, see Note 4.

[4] Amounts may not add due to rounding.

[5] Amounts may not add due to rounding.

[6] Amounts may not add due to rounding.